Cargando…

Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1–84): A Retrospective Cohort Study

INTRODUCTION: Patients with chronic hypoparathyroidism are at increased risk of cardiovascular disease. This study evaluated the risk of developing cardiovascular conditions over a period of 5 years in adult patients with chronic hypoparathyroidism treated with recombinant human parathyroid hormone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayodele, Olulade, Mu, Fan, Berman, Richard, Swallow, Elyse, Rejnmark, Lars, Gosmanova, Elvira O., Kaul, Sanjiv
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309129/ https://www.ncbi.nlm.nih.gov/pubmed/35696069 http://dx.doi.org/10.1007/s12325-022-02198-y

Ejemplares similares

Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study
por: Ayodele, Olulade, et al.
Publicado: (2022)

Risk of Chronic Kidney Disease in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1–84) Compared With a Historical Control Cohort
por: Gosmanova, Elvira, et al.
Publicado: (2021)

Serum Calcium Levels in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1–84) Compared With a Historical Control Cohort
por: Rejnmark, Lars, et al.
Publicado: (2021)

Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1–84)
por: Chen, Kristina S, et al.
Publicado: (2020)

Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation
por: Liao, E Pauline, et al.
Publicado: (2023)

OR07-03 Continuous Subcutaneous Delivery of RhPTH(1-84) by Pump in Adults with Hypoparathyroidism
por: Bove-Fenderson, Erin, et al.
Publicado: (2020)

Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1–84) treatment
por: Marcucci, G., et al.
Publicado: (2022)

Continuous rhPTH (1–34) treatment in chronic hypoparathyroidism
por: Fuss, Carmina Teresa, et al.
Publicado: (2020)

Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
por: Gosmanova, Elvira O., et al.
Publicado: (2021)

Effects of parathyroid hormone rhPTH(1–84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study
por: Clarke, Bart L., et al.
Publicado: (2016)

Risk of Cardiovascular Conditions in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
por: Gosmanova, Elvira O., et al.
Publicado: (2021)

MON-526 Risk of Cardiovascular (CV) Conditions in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

Subcutaneous Infusion of rhPTH(1-34) During Pregnancy and Nursing in a Woman With Autosomal Dominant Hypoparathyroidism 1
por: Shulman, Dorothy
Publicado: (2022)

Association of Calcium and Phosphate Levels with Incident Chronic Kidney Disease in Patients with Hypoparathyroidism: A Retrospective Case-Control Study
por: Gosmanova, Elvira O., et al.
Publicado: (2022)

Recent Trends in Hypoparathyroidism-Related Inpatient and Emergency Department Admissions and Costs in the United States
por: Kaul, Sanjiv, et al.
Publicado: (2023)

Initiation of Continuous rhPTH Infusion With Insulin Pump in an Inpatient Setting
por: Lindsay Mart, Faith, et al.
Publicado: (2023)

MON-522 Risk of Chronic Kidney Disease (CKD) and Its Progression in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

MON-523 Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis
por: Satterwhite, Julie, et al.
Publicado: (2010)

MON-524 Risk of Decline in Estimated Glomerular Filtration Rate (eGFR) in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

Graphene Oxide/RhPTH(1-34)/Polylactide Composite Nanofibrous Scaffold for Bone Tissue Engineering
por: Fei, Fan, et al.
Publicado: (2023)

Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review: Renal disease in chronic hypoparathyroidism
por: Gosmanova, Elvira O., et al.
Publicado: (2021)

Overexpression of Recombinant Human Teriparatide, rhPTH (1–34) in Escherichia coli : An Innovative Gene Fusion Approach
por: Bakhtiari, Nahid, et al.
Publicado: (2017)

OR21-1 The PaTH Forward Trial: Efficacy and Safety of TransCon PTH Through Week 84 for Adults With Hypoparathyroidism
por: Ahmed, Intekhab, et al.
Publicado: (2022)

The Effect of Recombinant Human Parathyroid Hormone (rhPTH) on Tendon-to-Bone Healing in a Rat Rotator Cuff Model
por: Duchman, Kyle R., et al.
Publicado: (2015)

Properties of a Stable and Sustained-Release Formulation of Recombinant Human Parathyroid Hormone (rhPTH) with Chitosan and Silk Fibroin Microparticles
por: Lv, Bi-Hua, et al.
Publicado: (2018)

Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
por: Ketteler, Markus, et al.
Publicado: (2021)

A Novel Approach for High Level Expression of Soluble Recombinant Human Parathyroid Hormone (rhPTH 1-34) in Escherichia coli
por: Hamedifar, Haleh, et al.
Publicado: (2013)

Safety and Efficacy of PTH 1‐34 and 1‐84 Therapy in Chronic Hypoparathyroidism: A Meta‐Analysis of Prospective Trials
por: Puliani, Giulia, et al.
Publicado: (2022)

SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

Hypoparathyroidism: Replacement Therapy with Parathyroid Hormone
por: Rejnmark, Lars, et al.
Publicado: (2015)

Therapy of Hypoparathyroidism by Replacement with Parathyroid Hormone
por: Rejnmark, Lars, et al.
Publicado: (2014)

A Phase I Randomized Trial of Once‐Daily Versus Twice‐Daily Recombinant Human Parathyroid Hormone (1‐84) for Hypoparathyroidism
por: Ing, Steven W., et al.
Publicado: (2023)

Total thyroidectomy: reduction in postoperative hypoparathyroidism
por: Reinke, Rasmus, et al.
Publicado: (2023)

Low health-related quality of life in hypoparathyroidism and need for PTH analog
por: Kontogeorgos, Georgios, et al.
Publicado: (2021)

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
por: Khan, Aliya A, et al.
Publicado: (2021)

TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension
por: Rubin, Mishaela R, et al.
Publicado: (2021)

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial
por: Khan, Aliya A, et al.
Publicado: (2022)

Psychometric Analysis of the Patient-Reported Hypoparathyroidism Symptom Diary Symptom Subscale Using Data from Two Clinical Trials
por: Nelson, Lauren, et al.
Publicado: (2023)

SAT-396 A Non-Surgical Animal Model of Hypoparathyroidism for Testing PTH Analogues
por: Ramezani-Pour, Narjes, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4vd1rpqav9709p3e57rh0p6poq